Remove 2025 Remove Healthcare Remove Pharmaceutical manufacturing
article thumbnail

WuXi STA breaks ground on new Delaware manufacturing facility

European Pharmaceutical Review

Contract research, development and manufacturing organisation (CRDMO) WuXi STA has broken ground on its new 190-acre pharmaceutical manufacturing campus in Middletown, Delaware, US. The WuXi STA Middletown facility is expected to begin operations in 2025.

article thumbnail

Global Health Equity: Moving From Wish List to To-Do List

Eversana Intouch

We must ensure our messaging is tailored to apply and resonate across cultures, languages, regulations and healthcare systems. Correspondingly, pharmaceutical manufacturers spend exponentially more on marketing healthcare, including more than $6 billion annually on direct-to-consumer advertising.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Year in review: EPR’s top stories of 2023

European Pharmaceutical Review

Pharmaceutical manufacturing Oligonucleotides Last month, the Centre for Process Innovation (CPI) announced a new Scotland-based manufacturing facility focusing on oligonucleotide therapeutics. According to CPI, the facility is set to be completed in late 2025.

article thumbnail

10 New Solutions, Strategies, and Devices to Boost Adherence

PM360

billion in 2025. One reason for this growth is an increasing demand for personalized healthcare technologies as patients look for advances in how healthcare is delivered following the pandemic. NovaXS is on a mission to simplify the medication self-administration process and improve remote healthcare adherence.

article thumbnail

CMS enters drug price negotiation arena in sea change for industry

Clarivate

In 2025, CMS will select another 15 Part D drugs for negotiations that will take effect in 2027. That compares to the $240.4 billion in spending across all Part D drugs that year (2022) and the $43.6 billion spent on all Part B drugs that same year.